uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease modifying therapies to patients
with severe disorders.
We believe our multiple partnerships and the regulatory approval of our lead product Glybera in the European Union for a subset of patients with LPLD provides validation for our approach .
AIPGENE Consortium Presents 1 Year Follow-Up Clinical Data from Acute Intermittent Porphyria Phase I Clinical Trial Using AAV5-PBGD Gene Therapy Candidate
uniQure to Present at the Leerink Partners Rare Disease Roundtable Conference
uniQure Announces Results for the Second Quarter and First Half of 2014 and Provides Update on Gene Therapy Programs
uniQure Acquires Cardiology Gene Therapy Company InoCard
Chiesi and uniQure Provide Update on Glybera® Launch